ZP 10000
Alternative Names: ET-3764; ZP-10000Latest Information Update: 20 Dec 2023
At a glance
- Originator Encycle Therapeutics
- Class Anti-inflammatories; Cyclic peptides
- Mechanism of Action Alpha4beta7 integrin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 01 Dec 2023 ZP 10000 is still in preclinical phase of development for Inflammatory bowel diseases in Denmark (PO)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Denmark (PO)
- 22 Oct 2019 Zealand Pharma acquired Encycle Therapeutics